Breadcrumb navigation

Pipeline

piplinetable

Personalized Neoantigen Vaccine for cancer treatment : TG4050

TG4050 is a virus-based therapeutic vaccine that incorporates a sequence of neoantigens (patient-specific mutations) selected by NEC‘s neoantigen prediction system into Transgene’s myvac®. It is designed to stimulate the immune system of patient in order to prime an innate and an adaptive response able to destroy tumor cells.

Details of clinical trial
Ovarian cancer (linked to clinicaltrials.gov)
Head and neck cancer(linked to clinicaltrials.gov)

Latest news

Relevant research paper

Personalized Neoantigen Vaccine : NECVAX NEO1

NECVAX NEO1 is a bacteria-based therapeutic vaccine that incorporates a sequence of neoantigens (patient-specific mutations) selected by NEC's neoantigen prediction system into Vaximm’s oral T-cell immunotherapy platform. It is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens.

Latest News